PledPharma AB
Advanced search
Log in
Press Room
Releases
Multimedia
About
Subscribe
Rights issue in PledPharma oversubscribed
5/24/2013 8:00 AM EST
PledPharma AB
Company Announcement
Rights issue in PledPharma oversubscribed
Stockholm, 2013-05-24 14:00 CEST (GLOBE NEWSWIRE) --
PledPharmas rights issue with subscription period from 6 May to 20 May 2013 was
oversubscribed by 38 percent. PledPharma receives approximately SEK 18.6
million before issue costs.
The rights issue was subscribed to approximately 95 percent with preferential
rights and the remaining 5 percent were subscribed for without preferential
rights. The new share issue was, thus, fully subscribed. Shares subscribed for
without preferential rights, will be allocated to shareholders who exercised
subscription rights in relation to the number of existing subscription rights
used by each shareholder.
“The oversubscription shows great interest in PledPharma and PledOx®. The
rights issue is done to expand PLIANT study with more study centers worldwide
to ensure implementation, and also to achieve greater flexibility and time to
implement the best...
PledPharma appoints advisor for the commercialization of PledOx®
5/6/2013 2:30 AM EST
PledPharma AB
Company Announcement
PledPharma appoints advisor for the commercialization of PledOx®
PledPharma intends to out-licence oncology compound PledOx starting in 2013...
Interim Report First Quarter 2013
4/18/2013 8:00 AM EST
PledPharma AB
Interim information
Interim Report First Quarter 2013
First patient treated in the PledOx™ phase IIb study, PLIANT
Stockholm, 2013-04-18 14:00 CEST (GLOBE...
PledPharma today announces that the MANAMI study is fully recruited
4/18/2013 7:29 AM EST
PledPharma AB
Company Announcement
PledPharma today announces that the MANAMI study is fully recruited
All patients were included in the current small investigator initiated...
PledPharma AB (publ) issues new shares
4/3/2013 12:58 PM EST
PledPharma AB
Company Announcement
PledPharma AB (publ) issues new shares
Specialty pharma company PledPharma proposes a rights issue of shares that can
provide the company...
Go-ahead for PledPharma to proceed with PLIANT study patient recruitment
2/26/2013 3:42 AM EST
PledPharma AB
Company Announcement
Go-ahead for PledPharma to proceed with PLIANT study patient recruitment
PledPharma has received green light from the DSMB (Drug Safety...
PledPharma AB (publ) Full Year Report 2012
2/21/2013 2:30 AM EST
PledPharma AB
Interim information
PledPharma AB (publ) Full Year Report 2012
First patient treated in the PledOx™ phase IIb study, PLIANT
Stockholm, 2013-02-21 08:30 CET...
PledPharma's patent application approved and issued in USA
2/20/2013 4:19 AM EST
PledPharma AB
Company Announcement
PledPharma's patent application approved and issued in USA
Stockholm, 2013-02-20 10:19 CET (GLOBE NEWSWIRE) -- PledPharma today...
First patient included into PledPharma’s PLIANT study
2/12/2013 3:02 PM EST
PledPharma AB
Company Announcement
First patient included into PledPharma’s PLIANT study
PledPharma announces today that the first patient has been enrolled in the
phase IIb...
PLIANT study starts in the U.S.
1/30/2013 4:55 AM EST
PledPharma AB
Company Announcement
PLIANT study starts in the U.S.
PledPharma expands recruitment to the dose-escalation phase of PLIANT study
with center in the...
FDA has approved IND application for clinical trial with PledOx in the U.S.
1/21/2013 2:30 AM EST
PledPharma AB
Company Announcement
FDA has approved IND application for clinical trial with PledOx in the U.S.
Stockholm, 2013-01-21 08:30 CET (GLOBE NEWSWIRE) -- PledPharma...
Nortal Investments Acquires Additional Shares in PledPharma
1/9/2013 9:37 AM EST
PledPharma AB
Company Announcement
Nortal Investments Acquires Additional Shares in PledPharma
Stockholm, 2013-01-09 15:37 CET (GLOBE NEWSWIRE) -- Staffan Persson,...
New Study Shows Superior Ability of PledOx to Reduce Chemotherapy Side Effects
12/27/2012 6:16 AM EST
PledPharma AB
Company Announcement
New Study Shows Superior Ability of PledOx to Reduce Chemotherapy Side Effects
Results of a preclinical study, comparing PledOx...
Nomination Committee for the 2013 Annual General Meeting in PledPharma AB
12/20/2012 9:01 AM EST
PledPharma AB
Company Announcement
Nomination Committee for the 2013 Annual General Meeting in PledPharma AB
Stockholm, 2012-12-20 15:01 CET (GLOBE NEWSWIRE) -- In consultation...
PledPharma Broadens Patient Base for the PLIANT Study
12/19/2012 2:30 AM EST
PledPharma AB
Company Announcement
PledPharma Broadens Patient Base for the PLIANT Study
The recruitment of patients for the Phase IIb study PLIANT is ongoing. To
broaden the...
PledPharma AB (publ) Interim report January-September 2012
10/26/2012 2:30 AM EST
PledPharma AB
Company Announcement
PledPharma AB (publ) Interim report January-September 2012
Patient screening ongoing ahead of inclusion in the PledOx™ Phase IIb...
PledPharma AB (publ) Interim report January – June 2012
8/24/2012 2:30 AM EST
PledPharma AB
Interim information
PledPharma AB (publ) Interim report January – June 2012
PledOx™ clinical study design approved
Stockholm, 2012-08-24 08:30 CEST (GLOBE...
PledPharma PledOx® clinical trial application approved
8/1/2012 2:30 AM EST
PledPharma AB
Company Announcement
PledPharma PledOx® clinical trial application approved
Stockholm, 2012-08-01 08:30 CEST (GLOBE NEWSWIRE) -- PledPharma (STO:PLED)
today...
PledPharma’s PledOx® safety studies positive
7/6/2012 2:30 AM EST
PledPharma AB
Company Announcement
PledPharma’s PledOx® safety studies positive
Stockholm, 2012-07-06 08:30 CEST (GLOBE NEWSWIRE) -- PledPharma (STO:PLED)
today announced...
PledPharma’s PledOx® project moves forward according to plan
6/27/2012 2:30 AM EST
PledPharma AB
Company Announcement
PledPharma’s PledOx® project moves forward according to plan
Stockholm, 2012-06-27 08:30 CEST (GLOBE NEWSWIRE) -- PledPharma (STO:PLED)
today...
Interim report January-March 2012
4/27/2012 2:59 AM EST
PledPharma AB
Interim information
Interim report January-March 2012
Stockholm, 2012-04-27 08:59 CEST (GLOBE NEWSWIRE) --
-- Net profit amounted to SEK -9.277k (-2.847k)
--...
SEE ALL NEWS
PledPharma AB
RSS
View more
Tweet
Media
more